Broncus Holding Valuation
Is 2216 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2216 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 2216's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 2216's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2216?
Key metric: As 2216 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 2216's PS Ratio? | |
|---|---|
| PS Ratio | 3.6x |
| Sales | US$8.73m |
| Market Cap | US$31.15m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 2216's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.5x | ||
2297 Rainmed Medical | 4x | n/a | HK$216.0m |
1612 Vincent Medical Holdings | 0.4x | 18.0% | HK$261.3m |
2407 Gaush Meditech | 1x | n/a | HK$1.5b |
1696 Sisram Medical | 0.5x | 12.8% | HK$1.5b |
2216 Broncus Holding | 3.6x | 25.6% | HK$242.5m |
Price-To-Sales vs Peers: 2216 is expensive based on its Price-To-Sales Ratio (3.6x) compared to the peer average (1.6x).
Price to Sales Ratio vs Industry
How does 2216's PS Ratio compare vs other companies in the HK Medical Equipment Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
1763 China Isotope & Radiation | 0.5x | n/a | US$435.58m |
1120 Arts Optical International Holdings | 0.3x | n/a | US$41.19m |
1612 Vincent Medical Holdings | 0.4x | 18.0% | US$33.57m |
2393 Yestar Healthcare Holdings | 0.06x | n/a | US$20.67m |
| 5 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 2216 is expensive based on its Price-To-Sales Ratio (3.6x) compared to the Hong Kong Medical Equipment industry average (3.2x).
Price to Sales Ratio vs Fair Ratio
What is 2216's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.6x |
| Fair PS Ratio | 2.6x |
Price-To-Sales vs Fair Ratio: 2216 is expensive based on its Price-To-Sales Ratio (3.6x) compared to the estimated Fair Price-To-Sales Ratio (2.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Sinopharm Group
HK$62.6b
Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.
1099
HK$20.05
7D
-0.7%
1Y
0.3%
OrbusNeich Medical Group Holdings
HK$3.4b
An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.
6929
HK$4.10
7D
-5.7%
1Y
-48.6%
Hygeia Healthcare Holdings
HK$10.2b
Offers oncology healthcare services in the People's Republic of China.
6078
HK$16.40
7D
-6.6%
1Y
-66.9%